Results 91 to 100 of about 10,425 (248)

Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - A systematic review.

PLoS ONE, 2019
BackgroundThe number of jurisdictions allowing access to medicinal cannabis has been steadily increasing since the state of California introduced legislation in 1996.
Kyle M Gardiner, Judith A Singleton, Janie Sheridan, Gregory J Kyle, Lisa M Nissen   +4 more
doaj   +1 more source

Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark, Mussie Msghina, Axel Nordenskjöld   +2 more
wiley   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

Flashbacks de um Canabista

Polymatheia, 2022
O presente artigo ensaístico concerne ao meu trabalho final do VII Curso de Cannabis Medicinal da UNIFESP. Idealizo aqui apresentar, de uma forma multilateral e por meio de recortes autobiográficos, as minhas reflexões sobre os usos da Cannabis.
Jan Clefferson Costa de Freitas
doaj  

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

From farm to bedside: Potential of medical cannabis in global health

Complementary Therapies in Medicine
Introduction: The growing opioid crisis and persistent global health disparities underscore the urgent need for alternative therapeutic strategies.
Maureen Bilinga Tendwa, Tejaswini Appidi, Brylyne Chitsunge, Michele Moreau, Blessed Okole, Lonji Kalombo, Abba Mallum, Twalib Ngoma, Daniel P. Weadock, Eric Tanifum, Simon Erridge, Mikael Sodergren, Rob Sims, Calvin Johnson, Ngeh Toyang, Henry Lowe, Bashkim Ziberi, Luc Richner, Sandra Carrillo, Stephen Avery, Judey Pretorius, Rachel Chikwamba, Fleury A.Nsole Biteghe, Peter Grinspoon, Gary Strichtartz, Sayeda Yasmin-Karim, Wilfred Ngwa   +26 more
doaj   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source